{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:02:51Z","timestamp":1792029771978,"version":"4.4.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Youth Foundation of Shandong Natural Science Foundation","award":["ZR2023QH239"],"award-info":[{"award-number":["ZR2023QH239"]}]},{"name":"ECCM Program of the Clinical Research Center of Shandong University","award":["2021SDUCRCB007"],"award-info":[{"award-number":["2021SDUCRCB007"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,29]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and hypothesis<\/jats:title>\n                    <jats:p>Immunoglobulin A nephropathy (IgAN) is the most common form of glomerulonephritis and a common cause of end-stage kidney disease. This study aimed to evaluate the effectiveness and safety of finerenone in combination with an angiotensin-converting enzyme inhibitor\/angiotensin-receptor blocker (ACEI\/ARB) regimen in IgAN patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our study was a single-center, observational, retrospective clinical study. Fifty-two primary IgAN patients were added. Patients were divided into two groups: the finerenone combined with ACEI\/ARB group and the ACEI\/ARB group. The primary endpoint was treatment response, defined as the percentage change in urinary protein\/creatinine ratio (UPCR) and estimated glomerular filtration rate (eGFR) from baseline to 6\u00a0months. The secondary endpoint was the safety of finerenone, with adverse events recorded during treatment. Clinical data were collected from IgAN patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 52 IgAN patients enrolled, 19 were in the finerenone combined with ACEI\/ARB group and 33 in the ACEI\/ARB group. At 6\u00a0months, the percentage change in UPCR was significantly greater in the finerenone combined with ACEI\/ARB group compared with the ACEI\/ARB group [\u201352.10% (interquartile range, IQR \u201365.71%, \u20136.12%) vs \u201321.25% (IQR \u201339.84%, \u20136.19%); P\u00a0=\u00a0.04]. Furthermore, the UPCR was lower in the finerenone combined with ACEI\/ARB group [0.41\u00a0g\/g (IQR 0.30, 0.72) vs 0.68\u00a0g\/g (IQR 0.49, 1.10); P\u00a0=\u00a0.024]. Serum albumin levels were higher in the finerenone combined with ACEI\/ARB group than in the ACEI\/ARB group (44.84\u00a0\u00b1\u00a02.35\u00a0g\/L vs 42.96\u00a0\u00b1\u00a03.27\u00a0g\/L; P\u00a0=\u00a0.033). No significant changes in eGFR were observed between the groups (P\u00a0=\u00a0.091). The response rate was significantly higher in the finerenone combined with ACEI\/ARB group compared with the ACEI\/ARB group (73.7% vs 39.4%, P\u00a0=\u00a0.017). No serious adverse events were observed in either group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In real-world settings, the finerenone combined with ACEI\/ARB regimen significantly improved outcomes in IgAN patients, effectively reducing proteinuria levels and increasing serum albumin levels, while maintaining relatively stable eGFR and exhibiting safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfaf240","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T12:34:20Z","timestamp":1762778060000},"page":"1129-1137","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness and safety of finerenone in IgA nephropathy patients"],"prefix":"10.1093","volume":"41","author":[{"given":"Kuipeng","family":"Yu","sequence":"first","affiliation":[{"name":"Qilu Hospital of Shandong University Department of Nephrology, , Jinan, Shandong ,","place":["China"]},{"name":"Qilu Hospital of Shandong University Department of Blood Purification, , Jinan, Shandong ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengren","family":"Li","sequence":"additional","affiliation":[{"name":"Qilu Hospital of Shandong University Department of Nephrology, , Jinan, Shandong ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Fan","sequence":"additional","affiliation":[{"name":"Qilu Hospital of Shandong University Department of Nephrology, , Jinan, Shandong ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhao","sequence":"additional","affiliation":[{"name":"Qilu Hospital of Shandong University Department of Nephrology, , Jinan, Shandong ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjie","family":"Wang","sequence":"additional","affiliation":[{"name":"Qilu Hospital of Shandong University Department of Nephrology, , Jinan, Shandong ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"bai","sequence":"additional","affiliation":[{"name":"Qilu Hospital of Shandong University Department of Nephrology, , Jinan, Shandong ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[{"name":"Qilu Hospital of Shandong University Department of Nephrology, , Jinan, Shandong ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangdong","family":"Yang","sequence":"additional","affiliation":[{"name":"Qilu Hospital of Shandong University Department of Nephrology, , Jinan, Shandong ,","place":["China"]},{"name":"Qilu Hospital of Shandong University Department of Blood Purification, , Jinan, Shandong ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"2026052900265620300_bib1","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/ki.2013.210","article-title":"Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease","volume":"84","author":"Barbour","year":"2013","journal-title":"Kidney Int"},{"key":"2026052900265620300_bib2","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N Engl J Med"},{"key":"2026052900265620300_bib3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1053\/j.ajkd.2021.03.007","article-title":"Association of treatment effects on early change in urine protein and treatment effects on GFR slope in IgA nephropathy: an individual participant meta-analysis","volume":"78","author":"Inker","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2026052900265620300_bib4","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.ajkd.2016.02.042","article-title":"Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis","volume":"68","author":"Inker","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2026052900265620300_bib5","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1002\/jcb.27648","article-title":"Efficacy and safety of angiotensin-converting enzyme inhibitors\/angiotensin receptor blocker therapy for IgA nephropathy: a meta-analysis of randomized controlled trials","volume":"120","author":"Ji","year":"2019","journal-title":"J Cell Biochem"},{"key":"2026052900265620300_bib6","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"2026052900265620300_bib7","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"2026052900265620300_bib8","doi-asserted-by":"publisher","first-page":"Cd003962","DOI":"10.1002\/14651858.CD003962.pub3","article-title":"Non-immunosuppressive treatment for IgA nephropathy","volume":"2024","author":"Tunnicliffe","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2026052900265620300_bib9","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s00125-023-06031-1","article-title":"Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists","volume":"67","author":"Savarese","year":"2024","journal-title":"Diabetologia"},{"key":"2026052900265620300_bib10","doi-asserted-by":"publisher","first-page":"9243","DOI":"10.3390\/ijms23169243","article-title":"Nonsteroidal mineralocorticoid receptor antagonism by finerenone-translational aspects and clinical perspectives across multiple organ systems","volume":"23","author":"Kolkhof","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026052900265620300_bib11","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1111\/bph.15747","article-title":"Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"179","author":"Kintscher","year":"2022","journal-title":"Br J Pharmacol"},{"key":"2026052900265620300_bib12","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/ejhf.2469","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial","volume":"24","author":"Filippatos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026052900265620300_bib13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"2026052900265620300_bib14","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2026052900265620300_bib15","doi-asserted-by":"publisher","first-page":"1242241","DOI":"10.3389\/fmed.2023.1242241","article-title":"Effect of SGLT2 inhibitors on the proteinuria reduction in patients with IgA nephropathy","volume":"10","author":"Dong","year":"2023","journal-title":"Front Med"},{"key":"2026052900265620300_bib16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1080\/1744666X.2024.2319132","article-title":"Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy","volume":"20","author":"Trachtman","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"2026052900265620300_bib17","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"2026052900265620300_bib18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"2026052900265620300_bib19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1080\/1744666X.2023.2206119","article-title":"Budesonide delayed-release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy","volume":"19","author":"Barratt","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"2026052900265620300_bib20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"2026052900265620300_bib21","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"2026052900265620300_bib22","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1093\/eurheartj\/ehac299","article-title":"Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"43","author":"Pandey","year":"2022","journal-title":"Eur Heart J"},{"key":"2026052900265620300_bib23","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026052900265620300_bib24","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3389\/fphar.2018.01131","article-title":"Finerenone attenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress","volume":"9","author":"Gonz\u00e1lez-Bl\u00e1zquez","year":"2018","journal-title":"Front Pharmacol"},{"key":"2026052900265620300_bib25","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"key":"2026052900265620300_bib26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41440-018-0158-6","article-title":"Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease","volume":"42","author":"Akira","year":"2019","journal-title":"Hypertens Res"},{"key":"2026052900265620300_bib27","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1007\/s11255-024-04142-1","article-title":"Effectiveness and safety of finerenone in Chinese CKD patients without diabetes: a retrospective, real-world study","volume":"56","author":"Li","year":"2024","journal-title":"Int Urol Nephrol"},{"key":"2026052900265620300_bib28","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s40620-025-02240-6","article-title":"Effectiveness and safety of finerenone in non-diabetic patients with IgA nephropathy","volume":"38","author":"Chen","year":"2025","journal-title":"J Nephrol"},{"key":"2026052900265620300_bib29","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1159\/000487901","article-title":"Clinicopathological features to predict progression of IgA nephropathy with mild proteinuria","volume":"43","author":"Ding","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"2026052900265620300_bib30","doi-asserted-by":"publisher","first-page":"e0150885","DOI":"10.1371\/journal.pone.0150885","article-title":"Proteinuria during follow-up period and long-term renal survival of childhood IgA nephropathy","volume":"11","author":"Koichi","year":"2016","journal-title":"PLoS One"},{"key":"2026052900265620300_bib31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2026052900265620300_bib32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ckj\/sfac234","article-title":"A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease","volume":"16","author":"Rajiv","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026052900265620300_bib33","doi-asserted-by":"publisher","first-page":"13711","DOI":"10.3390\/ijms252413711","article-title":"Finerenone in heart failure-a novel therapeutic approach","volume":"25","author":"Amalie","year":"2025","journal-title":"Int J Mol Sci"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf240\/65269449\/gfaf240.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/6\/1129\/65269449\/gfaf240.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/6\/1129\/65269449\/gfaf240.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:27:05Z","timestamp":1780028825000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/6\/1129\/8320542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,11,11]]},"published-print":{"date-parts":[[2026,5,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf240","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2025,11,11]]}}}